The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDiaceutics Regulatory News (DXRX)

Share Price Information for Diaceutics (DXRX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 98.00
Bid: 96.00
Ask: 98.00
Change: 0.00 (0.00%)
Spread: 2.00 (2.083%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 98.00
DXRX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

New Contract Wins

24 Jun 2021 07:00

RNS Number : 9186C
Diaceutics PLC
24 June 2021
 

24 June 2021

Diaceutics PLC

("Diaceutics" or "the Company")

 

Multiple contracts for Inherited Retinal Disease (IRD) in APAC, EU, and US markets

-

Diaceutics is providing data analytics and implementation solutions to enable seamless commercialisation of diagnostic testing for leading global pharmaceutical companies ahead of the launch of an innovative targeted therapy for IRD

-

Projects cover comprehensive mapping of IRD testing landscapes, including through the use of the Company's diagnostic commercialisation platform DXRX, and test commercialisation strategy implementation to ensure the right testing is in place at launch, supporting increased uptake of the therapy

-

Contracts awarded cover key regional footprint extending to Europe, the UK, APAC & the US

 

Diaceutics PLC, (AIM: DXRX), the diagnostics commercialisation company for precision testing, announces it has secured four projects with two leading pharmaceutical companies to solve real-world testing hurdles for the rare disease group: Inherited Retinal Disease (IRD). IRD has, until now, been a largely untreatable disease group causing severe vision loss or even blindness, affecting around two million people worldwide. The contracts demonstrate the applicability of the DXRX diagnostic commercialisation platform outside of the Company's core area of oncology.

The services will be delivered over the course of six months in 2021 across Europe, the UK, APAC & the US. The projects are in partnership with existing pharmaceutical customers of the Company and represent an expansion of its commercial relationship into a new therapy area, in line with the Company's 'land and expand' strategy, and the increased engagement of the customers with the DXRX platform. The contracts will deliver approximately £1.0 million revenue within 2021.

Peter Keeling, CEO and Founder of Diaceutics says, "Diaceutics is excited to be involved with these ground-breaking therapies for IRD, giving us an opportunity to bring our extensive knowledge of personalized medicine in the oncology field to rare disease and to help patients with IRD access the best treatments available. These new project wins across a new disease area show the confidence that leading pharma companies have in Diaceutics and our considerable expansion opportunity. Through utilising the DXRX platform, alongside our advisory services, the projects can be delivered efficiently, at scale, across multiple geographies, bringing together all the segments in the precision medicine diagnostics market required to facilitate change and ensure patients get the right treatment at the right time."

Diaceutics is the first to market with a unique diagnostic commercialisation platform, DXRX, allowing stakeholders in the precision medicine market to collaborate and shape the diagnostics marketplace, in real time. Via the DXRX platform, the Group is providing both data analysis services to pharmaceutical customers, collected within the platform to highlight key opportunities and hurdles that need to be considered for testing launch, and subsequent implementation solutions, in which key testing laboratories will be engaged to ensure seamless and high-quality diagnostic testing is in place at the time of therapy launch.

 

Enquiries:

 

Diaceutics PLC 

 

Peter Keeling, Chief Executive Officer

Via Alma PR 

Philip White, Chief Financial Officer 

 

 

 

Stifel Nicolaus Europe Limited (Nomad & Broker)

Tel: +44 (0)20 7710 7600

Ben Maddison

 

Stewart Wallace

 

Nick Adams

 

 

 

Alma PR

Tel: +44(0)20 3405 0205

Caroline Forde

diaceutics@almapr.co.uk

Robyn Fisher

 

Kieran Breheny

 

 

About Diaceutics

 

At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®.

 

DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
CNTUOSKRABUNUAR
Date   Source Headline
1st May 20247:00 amRNSNotice of Results & Presentations
30th Apr 20247:00 amRNSPDMR Shareholding/SIP and TVR
9th Apr 20247:00 amRNSAppointment of Amie Mc Neice as VP of Marketing
5th Apr 20241:40 pmRNSBlock Listing Return
3rd Apr 20247:00 amRNSPDMR Shareholding/Share Incentive Plan
2nd Apr 20247:00 amRNSDirector/PDMR/PCA Shareholding & TR1
21st Mar 20247:00 amRNSSignificant upgrade to Diaceutics' DXRX platform
19th Mar 20247:00 amRNSDiaceutics forms landmark industry Forum
7th Mar 20247:00 amRNSDirector/PDMR Shareholding
1st Mar 20249:00 amRNSPDMR Shareholding / SIP and TVR
27th Feb 20247:00 amRNSExpanded lab network and data capabilities
14th Feb 20241:00 pmRNSDiaceutics PLC - Strategic alliance with KPMG
5th Feb 20247:00 amRNSAppointment of VP, Scientific & Medical Services
1st Feb 202412:31 pmRNSPDMR Shareholding/Share Incentive Plan and TVR
30th Jan 20247:00 amRNSDiaceutics PLC – Trading Update
25th Jan 20241:16 pmRNSExercise of Warrant & Total Voting Rights
19th Jan 20247:00 amRNSDiaceutics PLC – Financial Calendar Update
29th Dec 20231:18 pmRNSPDMR Shareholding/Share Incentive Plan
30th Nov 202312:59 pmRNSPDMR Shareholding/Share Incentive Plan and TVR
30th Nov 20237:00 amRNSDiaceutics to attend Stifel Conference in NYC
21st Nov 202311:13 amRNSNotification of Major Holdings
31st Oct 202312:38 pmRNSPDMR Shareholding/SIP & Total Voting Rights
11th Oct 20231:47 pmRNSPDMR Shareholding/Share Incentive Plan and TVR
2nd Oct 20233:59 pmRNSBlock Listing Application to AIM
29th Sep 202311:19 amRNSHolding(s) in Company
26th Sep 20237:00 amRNSDiaceutics PLC – Half Year Results
26th Sep 20237:00 amRNSDiaceutics PLC - Planned CEO Transition
21st Sep 20232:37 pmRNSDiaceutics PLC – Directorate Changes
7th Sep 20237:00 amRNSAttending 10th Annual HealthTech Investment Forum
5th Sep 20237:00 amRNSNotice of Interim Results and Presentations
30th Aug 20232:56 pmRNSPDMR Shareholding/Share Incentive Plan
29th Aug 20237:00 amRNSDiaceutics launches daily alerts for DXRX platform
4th Aug 20237:00 amRNSCanaccord Genuity 43rd Annual Growth Conference
31st Jul 20233:19 pmRNSPDMR Shareholding/Share Incentive Plan
25th Jul 20237:00 amRNSTrading Update and Notice of Results
29th Jun 202312:07 pmRNSPDMR Shareholding/Share Incentive Plan
6th Jun 20237:00 amRNSPurchase and Sale of Shares and PDMR Shareholdings
5th Jun 20237:00 amRNSUSD 10.1 million multi-year enterprise engagement
31st May 20235:13 pmRNSPDMR Shareholding/Share Incentive Plan
19th May 202310:16 amRNSIssue of Share Options/PDMR Shareholdings
18th May 202311:46 amRNSResults of Annual General Meeting
11th May 20236:22 pmRNSPDMR Shareholdings
4th May 202310:34 amRNSPDMR shareholdings
28th Apr 20236:03 pmRNSPDMR Shareholding/Share Incentive Plan
26th Apr 20235:03 pmRNSPDMR Shareholding
25th Apr 20235:45 pmRNSNotice of AGM and Posting of Annual Report
17th Apr 20237:00 amRNSFinal Results
3rd Apr 20232:43 pmRNSPDMR Shareholding / Share Incentive Plan
20th Mar 20237:00 amRNSNotice of Results and Presentations
13th Mar 202310:15 amRNSRestoration - Diaceutics PLC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.